Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study

医学 减肥 中止 回顾性队列研究 肥胖 队列 药方 内科学 超重 儿科 药理学
作者
Mona Abdel‐Bary,Andrea Bródy,Jenna Schmitt,Karol Prieto,Amy Wetzel,Yen‐Yi Juo
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:27 (6): 3195-3200 被引量:6
标识
DOI:10.1111/dom.16331
摘要

AIMS: Despite excellent weight-loss outcomes in clinical trials, Glucagon-Like Peptide 1 receptor agonists (GLP1RA) face challenges with accessibility and compliance in clinical use. We seek to quantify how these barriers impact the long-term weight-loss efficacy of GLP1RAs in the real world. MATERIALS AND METHODS: In this retrospective cohort study, we analysed weight loss outcomes of patients who were prescribed GLP1RA for class 2-3 obesity treatment between January 2020 and November 2022 in a large non-profit healthcare system in the Midwest. The primary outcome is the two-year total weight loss percentage (TWL%). RESULTS: During the study period, there was a six-fold growth in GLP1RA prescription numbers. In total, 853 patients were prescribed GLP1RA for obesity treatment. Of these, 211 (24.7%) patients never received the drug and 304 (35.6%) patients had to discontinue treatment within 2 years. The most common reasons for discontinuation included loss to follow-up with the original prescriber (n = 81, 26.6%), side effects (n = 72, 23.7%) and cessation of insurance coverage (n = 65, 21.4%). Two years later, patients who stayed on GLP1RA experienced significantly more weight loss than those who never started it (difference 3.98%, 95% CI 1.57% to 6.41%, p = 0.001) and those who had stopped taking it (difference 5.82%, 95% CI 3.56% to 8.09%, p < 0.001). Patients who stopped GLP1RA within 2 years had similar weight loss to those who never started it (difference 1.83%, 95% CI -1.30% to 4.97%, p = 0.251). The average TWL% for patients who stayed on GLP1RA for 2 years is 9.22% (standard deviation 9.73%). CONCLUSIONS: Nearly half of the patients who were started on GLP1RA, a treatment intended for indefinite use, stopped taking GLP1RA within 2 years. Patients who stopped treatment experienced similar weight loss to those who never started treatment. For real-world patients who stayed on treatment for 2 years, a lower TWL% was observed than previously reported in clinical trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.4的应助被Code_king采纳,获得10
1秒前
星星发布了新的文献求助10
1秒前
2秒前
JQK发布了新的文献求助10
3秒前
Trenblin发布了新的文献求助10
3秒前
充电宝的应助被枕月采纳,获得10
3秒前
JamesPei的应助被花小羊采纳,获得10
4秒前
4秒前
青黛发布了新的文献求助10
5秒前
5秒前
阿琪完成签到 ,获得积分10
7秒前
栗子完成签到,获得积分20
7秒前
大模型的应助被LL采纳,获得10
7秒前
香蕉觅云的应助被王木木采纳,获得10
7秒前
tang发布了新的文献求助10
8秒前
momoli完成签到,获得积分10
8秒前
李爱国的应助被000000采纳,获得10
9秒前
ygtqcty完成签到,获得积分20
9秒前
Billy发布了新的文献求助10
9秒前
法法完成签到,获得积分10
10秒前
10秒前
11秒前
離1028完成签到 ,获得积分10
11秒前
11秒前
顾矜的应助被Trenblin采纳,获得10
12秒前
叶子发布了新的文献求助10
13秒前
14秒前
14秒前
14秒前
14秒前
Northing完成签到 ,获得积分10
14秒前
三白发布了新的文献求助10
14秒前
15秒前
辛勤若灵完成签到,获得积分10
15秒前
hermit发布了新的文献求助10
15秒前
炙热听莲完成签到 ,获得积分10
15秒前
WUT完成签到,获得积分0
16秒前
青黛发布了新的文献求助10
16秒前
大个的应助被zzc采纳,获得100
16秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177654
求助须知:如何正确求助?哪些是违规求助? 9568503
关于积分的说明 21799551
捐赠科研通 7772253
什么是DOI,文献DOI怎么找? 3432428
关于科研通互助平台的介绍 2556594
邀请新用户注册赠送积分活动 2478011